BOSTON & TORONTO--(BUSINESS WIRE)--BTL Industries, a leading developer and manufacturer of medical equipment for aesthetic medicine, physical therapy and cardiology, today announced Health Canada approval to market and distribute its EXILIS RadioFrequency (RF) device in the country. EXILIS Focused RF™ technology hit the “superfecta” with Canadian clearance for use in non-invasive body contouring, fat removal, wrinkle reduction and skin tightening. Health Canada approval is similar to U.S. Food and Drug Administration clearance.
Unlike traditional radiofrequency devices, EXILIS is intelligently engineered so that a trained professional can deliver the maximum thermal energy to the desired depth of penetration while monitoring skin temperature in real time. This clinical ability to beneficially affect only targeted tissue in the shortest amount of time makes EXILIS a highly effective aesthetic solution. Treatments are precise, quick and well-tolerated, providing impressive results with utmost patient safety and comfort.
Marcel Besse, President of BTL Aesthetics, said, “We are very pleased about the Health Canada clearance of EXILIS and are proud to be the first focused radiofrequency technology in North America to receive approval for four aesthetic indications. Securing these regulatory clearances indicates the integrity of our compelling data regarding EXILIS’ safety and efficacy.”
The launch of EXILIS RF in Canada will be spearheaded by BASIS Medical Technologies, well-established specialists in the development and distribution of groundbreaking medical aesthetic technologies. The company’s direct sales force will support EXILIS in the Canadian market where it holds exclusive market representation rights.
“We are excited to join forces with BASIS to introduce EXILIS to a new segment of professionals who seek a predictable aesthetic solution to wrinkles, lax skin and stubborn pockets of fat. We are confident that our partnership with BASIS will provide clinicians a global distribution and development platform that can help them expand their consumer base and achieve high patient satisfaction,” Mr. Besse added.
John McCahill, BASIS’ CEO, said, “We look forward to working in cooperation with our new partner to foster the continued success of its technology in Canada.” According to Mr. McCahill, EXILIS has the potential to be a win-win for physicians and patients. It delivers the convenience and fast results patients want with Focused RF technology that is safer and more targeted than conventional rival treatments. At the same time, it is economical for physician practices because EXILIS is affordable, there are no costly disposables, and no topical anesthesia is required. “It nicely fills a void in the physician’s menu of services by providing one RF platform with multiple applications and high utilization.”
About BTL Industries Limited
BTL Industries Limited designs, manufactures and sells medical equipment for physical therapy, cardiology, and medical aesthetics. Headquartered in Prague, the Czech Republic, the Company is among the world’s five largest physical therapy manufacturers. For the past 18 years, BTL Industries supplies its products through distributors designated for each country, or through its sales subsidiaries. Its major markets include the European Union, East Asian markets, and the United States.
Since 2009, BTL Aesthetics division takes the company into aesthetic medicine with non-surgical devices that represent the best in skin tightening, anti-cellulite care, anti-wrinkle treatment, body shaping and fat reduction. For more information, please visit www.exilis.com.
About BASIS Medical Technologies
BASIS Medical Technologies (www.basismedtech.ca) distributes internationally through a network of experienced vendors around the globe. In addition to the reach that this structure provides, BASIS also benefits from the expertise and knowledge of our distributors in their local markets. It partners, in turn, benefit from the Company’s international profile, refined sales and marketing materials and regional rights to their portfolio of superior products and pipeline of disruptive technologies.